Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)

[1]  H. Einsele,et al.  A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma , 2003, Bone Marrow Transplantation.

[2]  N. Schmitz,et al.  Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. , 2002, Blood.

[3]  N. Kröger,et al.  Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. , 2002, Blood.

[4]  B. Barlogie,et al.  High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. , 2001, Blood.

[5]  G. Gahrton,et al.  Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.

[6]  M. Attal,et al.  Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation , 2001, Leukemia.

[7]  N. Kröger,et al.  Anti-Thymocyte-Globulin as part of the preparative regimen prevents graft failure and severe Graft versus Host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors , 2001, Annals of Hematology.

[8]  N. Kröger,et al.  Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma , 2001, British journal of haematology.

[9]  C. Schmoor,et al.  Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin , 2000 .

[10]  C. Huff,et al.  Allogeneic bone marrow transplantation (ALLO BMT): Role of t cell depletion (TCD) and graft versus host disease (GVHD) , 2000 .

[11]  N. Kröger,et al.  Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow , 1999, Bone Marrow Transplantation.

[12]  A. Zander,et al.  Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients , 1999, Bone Marrow Transplantation.

[13]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[14]  A. Palumbo,et al.  Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma , 1998, Bone Marrow Transplantation.

[15]  E. Santagostino,et al.  High Prevalence of Serum Cryoglobulins in Multitransfused Hemophilic Patients With Chronic Hepatitis C , 1998 .

[16]  J. Cornelissen,et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. , 1997, Blood.

[17]  R. Marcus,et al.  Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. , 1996, Blood.

[18]  R. Storb,et al.  Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.

[19]  H. Nieuwenhuis,et al.  Graft-versus-myeloma effect in two cases , 1996, The Lancet.

[20]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.

[21]  A. Hagenbeek,et al.  Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[23]  D. Reece,et al.  Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. , 1995, Bone marrow transplantation.

[24]  A. Freedman,et al.  Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. , 1993, Blood.

[25]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[26]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.